Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 26,100 shares, a decrease of 13.3% from the August 31st total of 30,100 shares. Approximately 4.3% of the company’s stock are sold short. Based on an average daily trading volume, of 8,700 shares, the short-interest ratio is currently 3.0 days.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on RKDA shares. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Arcadia Biosciences in a research report on Wednesday, August 21st. StockNews.com initiated coverage on Arcadia Biosciences in a research report on Saturday. They set a “sell” rating for the company.
Read Our Latest Report on RKDA
Arcadia Biosciences Stock Down 0.4 %
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). The firm had revenue of $1.31 million for the quarter, compared to the consensus estimate of $0.95 million. Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. During the same quarter in the prior year, the firm earned ($2.64) EPS. As a group, equities research analysts anticipate that Arcadia Biosciences will post -1.7 earnings per share for the current fiscal year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- Want to Profit on the Downtrend? Downtrends, Explained.
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- MarketBeat Week in Review – 9/23 – 9/27
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.